Evidence map›Paper›PMID 30051419›Full record

ArticleNeurotoxicity research2018

Differential Morphological and Biochemical Recovery from Chemotherapy-Induced Peripheral Neuropathy Following Paclitaxel, Ixabepilone, or Eribulin Treatment in Mouse Sciatic Nerves.

B M Cook, K M Wozniak, D A Proctor, R B Bromberg, Y Wu, B S Slusher, B A Littlefield, M A Jordan, L Wilson, Stuart C Feinstein

Abstract read
PubMed Publisher
In one paragraph

Article in Neurotoxicity research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Mechanisms of Chemotherapy-Induced Neurotoxicity.Frontiers in pharmacology · 2022
    Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

B M CookNeuroscience Research Institute, University of California Santa Barbara, Santa Barbara, CA, 93106, USA.
K M WozniakJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA.
D A ProctorDepartment of Molecular, Cellular, and Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, 93016, USA.
R B BrombergDepartment of Molecular, Cellular, and Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, 93016, USA.
Y WuJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA.
B S SlusherJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA.
B A LittlefieldScientific Administration, Eisai Research Institute, Andover, MA, 01810, USA.
M A JordanNeuroscience Research Institute, University of California Santa Barbara, Santa Barbara, CA, 93106, USA.
L WilsonNeuroscience Research Institute, University of California Santa Barbara, Santa Barbara, CA, 93106, USA.
Stuart C FeinsteinNeuroscience Research Institute, University of California Santa Barbara, Santa Barbara, CA, 93106, USA. feinstei@lifesci.ucsb.edu.ORCID http://orcid.org/0000-0002-1662-6759
University of California, Santa Barbara · USJohns Hopkins University · USEisai (United States) · US

Funding

Eisai Inc. Research Support AgreementNational Institutes of Health R01CA161056
6 · The paper itself

Abstract

The reversibility of chemotherapy-induced peripheral neuropathy (CIPN), a disabling and potentially permanent side effect of microtubule-targeting agents (MTAs), is becoming an increasingly important issue as treatment outcomes improve. The molecular mechanisms regulating the variability in time to onset, severity, and time to recovery from CIPN between the common MTAs paclitaxel and eribulin are unknown. Previously (Benbow et al. in Neurotox Res 29:299-313, 2016), we found that after 2 weeks of a maximum tolerated dose (MTD) in mice, paclitaxel treatment resulted in severe reductions in axon area density, higher frequency of myelin abnormalities, and increased numbers of Schwann cell nuclei in sciatic nerves. Biochemically, eribulin induced greater microtubule-stabilizing effects than paclitaxel. Here, we extended these comparative MTD studies to assess the recovery from these short-term effects of paclitaxel, eribulin, and a third MTA, ixabepilone, over the course of 6 months. Paclitaxel induced a persistent reduction in axon area density over the entire 6-month recovery period, unlike ixabepilone- or eribulin-treated animals. The abundance of myelin abnormalities rapidly declined after cessation of all drugs but recovered most slowly after paclitaxel treatment. Paclitaxel- and ixabepilone- but not eribulin-treated animals exhibited increased Schwann cell numbers during the recovery period. Tubulin composition and biochemistry rapidly returned from MTD-induced levels of α-tubulin, acetylated α-tubulin, and end-binding protein 1 to control levels following cessation of drug treatment. Taken together, sciatic nerve axons recovered more rapidly from morphological effects in eribulin- and ixabepilone-treated animals than in paclitaxel-treated animals and drug-induced increases in protein expression levels following paclitaxel and eribulin treatment were relatively transient.

Indexed as

Sciatic NeuropathyAnimalsAntineoplastic AgentsDisease Models, AnimalEpothilonesFemaleFuransIntermediate FilamentsKetonesMiceMice, Inbred BALB CMicrotubule-Associated ProteinsMyelin SheathPaclitaxelPolyether PolyketidesRecovery of FunctionAntineoplastic AgentsEB1 protein, mouseEpothiloneseribulinFuransixabepiloneKetonesMicrotubule-Associated ProteinsPaclitaxelPolyether PolyketidesS100 ProteinsTubulinChemotherapy-induced peripheral neuropathyEribulinIxabepiloneMicrotubulesPaclitaxelSciatic nerve

Identifiers

PMID30051419
OpenAlexW2884658746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.